CNS Cancers

Addition of EGFR-Targeting Vaccine to Temozolomide in EGFRvIII-Expressing Glioblastoma

The phase III ACT IV study has shown no survival benefit of adding rindopepimut, a vaccine targeting the epidermal growth factor receptor (EGFR) deletion mutation EGFRvIII...

Neuroendocrine Tumors

Health-Related Quality of Life in Everolimus-Treated Patients With Neuroendocrine Tumors

As reported in The Lancet Oncology by Pavel and colleagues, no significant difference in deterioration of health-related quality of life was observed with everolimus...

Hepatobiliary Cancer

Individualized Adaptive Stereotactic Body Radiotherapy for Primary and Metastatic Liver Tumors

In a single-center phase II study reported in JAMA Oncology, Feng and colleagues found that individualized adaptive stereotactic body radiotherapy achieved high rates of local tumor control...


Advertisement

More Top Stories

Bladder Cancer

Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis

The Roller Coaster

  The following essay by Shaker R. Dakhil, MD, FACP, is adapted, with permission, from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and...

Advertisement

U.S. Incidence and Projected Rise of Merkel Cell Carcinoma

The number of U.S. cases of Merkel cell carcinoma is rising about six times faster than most other cancers, and at nearly twice the rate of melanoma. Paulson et al reported these findings in The Journal of the American Academy of Dermatology, which are based on research conducted at the University...

Gastrointestinal Cancer

Khaldoun Almhanna, MD, MPH, on Gastric Cancer: Results From the CCOG 1102 Trial

Breast Cancer

Bone-Modifying Agents in Metastatic Breast Cancer: Time to De-escalate Dosing Intervals

AS REVIEWED in this issue of The ASCO Post, ASCO and Cancer Care Ontario (CCO) have issued an updated guideline on the role of bone-modifying agents in metastatic breast cancer.1 The updated guideline supports a change in clinical practice for our patients with breast cancer and bone metastasis....

Highlights From the 2018 Gastrointestinal and Genitourinary Cancers Symposia

THE 2018 GASTROINTESTINAL CANCERS SYMPOSIUM was held January 18–20, and the 2018 Genitourinary Cancers Symposium was held February 8–10. Help keep your patients informed by directing them to www.Cancer.Net/blog to read about the most exciting research presented at these conferences. ■ © 2018....

Serum Bone Biomarkers in Early Breast Cancer and Risk of Bone Metastasis

In a study reported in the Journal of the National Cancer Institute, Brown et al found that the serum bone biomarkers P1NP, CTX, and 1-CTP showed good prognostic ability for bone metastasis in patients in the phase III AZURE (BIG01/04) trial of adjuvant zoledronic acid in early breast cancer....

Gastroesophageal Cancer

David H. Ilson, MD, PhD, on Improving Esophageal Cancer Outcomes: Future Directions

Viviane Tabar, MD, Named Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center

VIVIANE TABAR, MD, has been named the new Chair of the Department of Neurosurgery at Memorial Sloan Kettering Cancer Center (MSK).  Dr. Tabar has been a faculty member at MSK for more than 15 years and is currently the Theresa C. Feng Chair for Neurosurgical Oncology and the Vice Chair for...

Advertisement

Dose Rounding of Anticancer Agents: Hematology/Oncology Pharmacy Association Position Statement

As reported in the Journal of Oncology Practice by Fahrenbruch et al, the Hematology/Oncology Pharmacy Association (HOPA) has issued a position statement on dose rounding of biologic and cytotoxic anticancer agents. To formulate the position statement, the HOPA standards committee organized a work ...